Sphingolipids as modulators of cancer cell death: Potential therapeutic targets

Biochimica et Biophysica Acta - Biomembranes

Volumn 1758, Issue 12, 2006, Pages 2104-2120

  Ségui, Bruno ^a   Andrieu Abadie, Nathalie ^a   Jaffrézou, Jean Pierre ^a   Benoist, Hervé ^a   Levade, Thierry ^a  

^a INSERM   (France)

Author keywords

Apoptosis; Autophagy; Caspase; Ceramide; Lysosome; Sphingolipid

Indexed keywords

2 (4 ETHYL 1 PIPERAZINYL) 4 PHENYLQUINOLINE DIMALEATE; 2 (N ADAMANTOYL)OCTADECEN 1,3 DIOL; 2 (N MYRISTOYLAMINO) 1 (4' NITROPHENYL) 1,3 PROPANEDIOL; 2 (N,N,N TRIMETHYLAMINO) 1 (N TETRADECANOYL 4 AMINOPHENYL) 1,3 PROPANEDIOL; 2 ACETYLAMINO 3 OCTADECEN 1,3 DIOL; 2 N MYRISTOYLAMINO 1 PHENYL 1 PROPANOL; 2 OCTANOYLAMIDOOCTADECADIENE 1,3 DIOL; AD 2687; AD 2765; ANTINEOPLASTIC AGENT; B 13; CASPASE; CERAMIDE; CERAMIDE DERIVATIVE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FINGOLIMOD; GALACTOSYLCERAMIDE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; N OLEOYL (2 AMINO 1,3 PROPANEDIOL); N,N DIMETHYLSPHINGOSINE; PHENETHYLISOTHIOCYANATE SPHINGANINE; S 18; SPHINGANINE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE DERIVATIVE; THERMOZYMOCIDIN; THIOURACIL CERAMIDE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CELL; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENETIC MANIPULATION; HUMAN; IC 50; IMMUNE RESPONSE; LIPID METABOLISM; LYSOSOME; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; HUMANS; NEOPLASMS; SPHINGOLIPIDS;

EID: 33845291121     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2006.05.024     Document Type: Review

References (226)

1. Leist M., and Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev., Mol. Cell Biol. 2 (2001) 589-598
2. Wyllie A.H., and Golstein P. More than one way to go. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11-13
3. Broker L.E., Kruyt F.A., and Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 11 (2005) 3155-3162
4. Kroemer G., El-Deiry W.S., Golstein P., Peter M.E., Vaux D., Vandenabeele P., Zhivotovsky B., Blagosklonny M.V., Malorni W., Knight R.A., Piacentini M., Nagata S., and Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 12 Suppl. 2 (2005) 1463-1467
5. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev., Cancer 2 (2002) 277-288
6. Decaudin D., Geley S., Hirsch T., Castedo M., Marchetti P., Macho A., Kofler R., and Kroemer G. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 57 (1997) 62-67
7. Allouche M., Bettaieb A., Vindis C., Rousse A., Grignon C., and Laurent G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene 14 (1997) 1837-1845
8. Dbaibo G.S., Perry D.K., Gamard C.J., Platt R., Poirier G.G., Obeid L.M., and Hannun Y.A. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J. Exp. Med. 185 (1997) 481-490
9. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.I., Jones D.P., and Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-1132
10. Lam M., Dubyak G., Chen L., Nunez G., Miesfeld R.L., and Distelhorst C.W. Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6569-6573
11. Hatano M., Mizuno M., and Yoshida J. Enhancement of C2-ceramide antitumor activity by small interfering RNA on X chromosome-linked inhibitor of apoptosis protein in resistant human glioma cells. J. Neurosurg. 101 (2004) 119-127
12. Birkle S., Zeng G., Gao L., Yu R.K., and Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 85 (2003) 455-463
13. Bektas M., and Spiegel S. Glycosphingolipids and cell death. Glycoconjugate J. 20 (2004) 39-47
14. Kanazawa J., Ohta S., Shitara K., Fujita F., Fujita M., Hanai N., Akinaga S., and Okabe M. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis. Cancer Immunol. Immunother. 49 (2000) 253-258
15. Scott A.M., Liu Z., Murone C., Johns T.G., MacGregor D., Smyth F.E., Lee F.T., Cebon J., Davis I.D., Hopkins W., Mountain A.J., Rigopoulos A., Hanai N., and Old L.J. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun. 5 (2005) 3
16. Chapman P.B. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr. Opin. Invest. Drugs 4 (2003) 710-715
17. Zeng G., Li D.D., Gao L., Birkle S., Bieberich E., Tokuda A., and Yu R.K. Alteration of ganglioside composition by stable transfection with antisense vectors against GD3-synthase gene expression. Biochemistry 38 (1999) 8762-8769
18. Zeng G., Gao L., Birkle S., and Yu R.K. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res. 60 (2000) 6670-6676
19. Deng W., Li R., Guerrera M., Liu Y., and Ladisch S. Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology 12 (2002) 145-152
20. Saha S., and Mohanty K.C. Correlation of gangliosides GM2 and GM3 with metastatic potential to lungs of mouse B16 melanoma. J. Exp. Clin. Cancer Res. 22 (2003) 125-134
21. Carr A., Mazorra Z., Alonso D.F., Mesa C., Valiente O., Gomez D.E., Perez R., and Fernandez L.E. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res. 11 (2001) 219-227
22. Irie R.F., Ollila D.W., O'Day S., and Morton D.L. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol. Immunother. 53 (2004) 110-117
23. Satoh M., Handa K., Saito S., Tokuyama S., Ito A., Miyao N., Orikasa S., and Hakomori S. Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential. Cancer Res. 56 (1996) 1932-1938
24. Steelant W.F., Kawakami Y., Ito A., Handa K., Bruyneel E.A., Mareel M., and Hakomori S. Monosialyl-Gb5 organized with cSrc and FAK in GEM of human breast carcinoma MCF-7 cells defines their invasive properties. FEBS Lett. 531 (2002) 93-98
25. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10231-10233
26. Hakomori Si S.I. Inaugural article: the glycosynapse. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 225-232
27. Hakomori S. Traveling for the glycosphingolipid path. Glycoconjugate J. 17 (2000) 627-647
28. Crespo F.A., Sun X., Cripps J.G., and Fernandez-Botran R. The immunoregulatory effects of gangliosides involve immune deviation favoring type 2 T cell responses. J. Leukocyte Biol. 79 (2006) 586-595
29. Yamaji T., Teranishi T., Alphey M.S., Crocker P.R., and Hashimoto Y. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J. Biol. Chem. 277 (2002) 6324-6332
30. Nicoll G., Avril T., Lock K., Furukawa K., Bovin N., and Crocker P.R. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur. J. Immunol. 33 (2003) 1642-1648
31. Peguet-Navarro J., Sportouch M., Popa I., Berthier O., Schmitt D., and Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170 (2003) 3488-3494
32. Wolfl M., Batten W.Y., Posovszky C., Bernhard H., and Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin. Exp. Immunol. 130 (2002) 441-448
33. McKallip R., Li R., and Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. 163 (1999) 3718-3726
34. Ravindranath M.H., Gonzales A., Soh D., Nishimoto K., Tam W.Y., Bilchik A., Morton D.L., and O'Day S. Interleukin-2 binds to ganglioside GD(1b). Biochem. Biophys. Res. Commun. 283 (2001) 369-373
35. Sorice M., Pavan A., Misasi R., Sansolini T., Garofalo T., Lenti L., Pontieri G.M., Frati L., and Torrisi M.R. Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes. Scand. J. Immunol. 41 (1995) 148-156
36. Irani D.N., Lin K.I., and Griffin D.E. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J. Immunol. 157 (1996) 4333-4340
37. Rayman P., Wesa A.K., Richmond A.L., Das T., Biswas K., Raval G., Storkus W.J., Tannenbaum C., Novick A., Bukowski R., and Finke J. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin. Cancer Res. 10 (2004) 6360S-6366S
38. Shen W., Falahati R., Stark R., Leitenberg D., and Ladisch S. Modulation of CD4 Th cell differentiation by ganglioside GD1a in vitro. J. Immunol. 175 (2005) 4927-4934
39. Gomez-Munoz A. Ceramide-1-phosphate: a novel regulator of cell activation. FEBS Lett. 562 (2004) 5-10
40. Kakugawa Y., Wada T., Yamaguchi K., Yamanami H., Ouchi K., Sato I., and Miyagi T. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10718-10723
41. Cuvillier O., Nava V.E., Murthy S.K., Edsall L.C., Levade T., Milstien S., and Spiegel S. Sphingosine generation, cytochrome c release, and activation of caspase-7 in doxorubicin-induced apoptosis of MCF7 breast adenocarcinoma cells. Cell Death Differ. 8 (2001) 162-171
42. Cuvillier O., and Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 98 (2001) 2828-2836
43. English D., Brindley D.N., Spiegel S., and Garcia J.G. Lipid mediators of angiogenesis and the signalling pathways they initiate. Biochim. Biophys. Acta 1582 (2002) 228-239
44. Saba J.D., and Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ. Res. 94 (2004) 724-734
45. Limaye V., Li X., Hahn C., Xia P., Berndt M.C., Vadas M.A., and Gamble J.R. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 105 (2005) 3169-3177
46. Clair T., Aoki J., Koh E., Bandle R.W., Nam S.W., Ptaszynska M.M., Mills G.B., Schiffmann E., Liotta L.A., and Stracke M.L. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 63 (2003) 5446-5453
47. Philip M., Rowley D.A., and Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol. 14 (2004) 433-439
48. Pettus B.J., Bielawski J., Porcelli A.M., Reames D.L., Johnson K.R., Morrow J., Chalfant C.E., Obeid L.M., and Hannun Y.A. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J. 17 (2003) 1411-1421
49. Graler M.H., and Goetzl E.J. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim. Biophys. Acta 1582 (2002) 168-174
50. Rosen H., and Goetzl E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev., Immunol. 5 (2005) 560-570
51. Wang W., Graeler M.H., and Goetzl E.J. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 19 (2005) 1731-1733
52. van der Vliet H.J., Molling J.W., von Blomberg B.M., Nishi N., Kolgen W., van den Eertwegh A.J., Pinedo H.M., Giaccone G., and Scheper R.J. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin. Immunol. 112 (2004) 8-23
53. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., Kondo E., Harada M., Koseki H., Nakayama T., Tanaka Y., and Taniguchi M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5690-5693
54. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., and Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
55. Wu D.Y., Segal N.H., Sidobre S., Kronenberg M., and Chapman P.B. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198 (2003) 173-181
56. Ogretmen B., and Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev., Cancer 4 (2004) 604-616
57. Mengubas K., Riordan F.A., Bravery C.A., Lewin J., Owens D.L., Mehta A.B., Hoffbrand A.V., and Wickremasinghe R.G. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism. Oncogene 18 (1999) 2499-2506
58. Jones B.E., Lo C.R., Srinivasan A., Valentino K.L., and Czaja M.J. Ceramide induces caspase-independent apoptosis in rat hepatocytes sensitized by inhibition of RNA synthesis. Hepatology 30 (1999) 215-222
59. Kim W.H., Choi C.H., Kang S.K., Kwon C.H., and Kim Y.K. Ceramide induces non-apoptotic cell death in human glioma cells. Neurochem. Res. 30 (2005) 969-979
60. Zhao S., Yang Y.N., and Song J.G. Ceramide induces caspase-dependent and -independent apoptosis in A-431 cells. J. Cell. Physiol. 199 (2004) 47-56
61. Thon L., Mohlig H., Mathieu S., Lange A., Bulanova E., Winoto-Morbach S., Schutze S., Bulfone-Paus S., and Adam D. Ceramide mediates caspase-independent programmed cell death. FASEB J. 19 (2005) 1945-1956
62. Chmura S.J., Nodzenski E., Beckett M.A., Kufe D.W., Quintans J., and Weichselbaum R.R. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 57 (1997) 1270-1275
63. Michael J.M., Lavin M.F., and Watters D.J. Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Cancer Res. 57 (1997) 3600-3605
64. Bruno A.P., Laurent G., Averbeck D., Demur C., Bonnet J., Bettaieb A., Levade T., and Jaffrezou J.P. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ. 5 (1998) 172-182
65. Itoh M., Kitano T., Watanabe M., Kondo T., Yabu T., Taguchi Y., Iwai K., Tashima M., Uchiyama T., and Okazaki T. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin. Cancer Res. 9 (2003) 415-423
66. Granot T., Milhas D., Carpentier S., Dagan A., Segui B., Gatt S., and Levade T. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. Leukemia 20 (2006) 392-399
67. Cuvillier O. Sphingosine in apoptosis signaling. Biochim. Biophys. Acta 1585 (2002) 153-162
68. Malisan F., and Testi R. GD3 ganglioside and apoptosis. Biochim. Biophys. Acta 1585 (2002) 179-187
69. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381 (1996) 800-803
70. Grazide S., Terrisse A.D., Lerouge S., Laurent G., and Jaffrezou J.P. Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines. J. Biol. Chem. 279 (2004) 18256-18261
71. Kroemer G., and Jaattela M. Lysosomes and autophagy in cell death control. Nat. Rev., Cancer 5 (2005) 886-897
72. Tardy C., Codogno P., Autefage H., Levade T., and Andrieu-Abadie N. Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle). Biochim. Biophys. Acta 1765 (2006) 101-125
73. Kagedal K., Zhao M., Svensson I., and Brunk U.T. Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem. J. 359 (2001) 335-343
74. Werneburg N.W., Guicciardi M.E., Bronk S.F., and Gores G.J. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am. J. Physiol.: Gastrointest. Liver Physiol. 283 (2002) G947-G956
75. Caruso J.A., Mathieu P.A., and Reiners Jr. J.J. Sphingomyelins suppress the targeted disruption of lysosomes/endosomes by the photosensitizer NPe6 during photodynamic therapy. Biochem. J. 392 (2005) 325-334
76. Werneburg N., Guicciardi M.E., Yin X.M., and Gores G.J. Tumor necrosis factor-{alpha}-mediated lysosomal permeabilization is FAN and caspase 8/bid-dependent. Am. J. Physiol.: Gastrointest. Liver Physiol. 287 (2004) G436-G443
77. Heinrich M., Wickel M., Schneider-Brachert W., Sandberg C., Gahr J., Schwandner R., Weber T., Saftig P., Peters C., Brunner J., Kronke M., and Schutze S. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 18 (1999) 5252-5263
78. Heinrich M., Neumeyer J., Jakob M., Hallas C., Tchikov V., Winoto-Morbach S., Wickel M., Schneider-Brachert W., Trauzold A., Hethke A., and Schutze S. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ. 11 (2004) 550-563
79. Kashkar H., Wiegmann K., Yazdanpanah B., Haubert D., and Kronke M. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J. Biol. Chem. 280 (2005) 20804-20813
80. Tardy C., Tyynela J., Hasilik A., Levade T., and Andrieu-Abadie N. Stress-induced apoptosis is impaired in cells with a lysosomal targeting defect but is not affected in cells synthesizing a catalytically inactive cathepsin D. Cell Death Differ. 10 (2003) 1090-1100
81. Beaujouin M., Baghdiguian S., Glondu-Lassis M., Berchem G., and Liaudet-Coopman E. Overexpression of both catalytically active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity. Oncogene 25 (2006) 1967-1973
82. Taha T.A., Kitatani K., Bielawski J., Cho W., Hannun Y.A., and Obeid L.M. TNF induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J. Biol. Chem. 280 (2005) 17196-17202
83. Puranam K.L., Guo W.X., Qian W.H., Nikbakht K., and Boustany R.M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol. Genet. Metab. 66 (1999) 294-308
84. Rylova S.N., Amalfitano A., Persaud-Sawin D.A., Guo W.X., Chang J., Jansen P.J., Proia A.D., and Boustany R.M. The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res. 62 (2002) 801-808
85. Tardy C., Autefage H., Garcia V., Levade T., and Andrieu-Abadie N. Mannose 6-phosphorylated proteins are required for tumor necrosis factor-induced apoptosis: defective response in I-cell disease fibroblasts. J. Biol. Chem. 279 (2004) 52914-52923
86. Lockshin R.A., and Zakeri Z. Apoptosis, autophagy, and more. Int. J. Biochem. Cell Biol. 36 (2004) 2405-2419
87. Ogier-Denis E., and Codogno P. Autophagy: a barrier or an adaptive response to cancer?. Biochim. Biophys. Acta 1603 (2003) 113-128
88. Scarlatti F., Bauvy C., Ventruti A., Sala G., Cluzeaud F., Vandewalle A., Ghidoni R., and Codogno P. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 279 (2004) 18384-18391
89. Daido S., Kanzawa T., Yamamoto A., Takeuchi H., Kondo Y., and Kondo S. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res. 64 (2004) 4286-4293
90. Lavieu G., Scarlatti F., Sala G., Carpentier S., Levade T., Ghidoni R., Botti J., and Codogno P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J. Biol. Chem. 281 (2006) 8518-8527
91. Kanazawa T., Nakamura S., Momoi M., Yamaji T., Takematsu H., Yano H., Sabe H., Yamamoto A., Kawasaki T., and Kozutsumi Y. Inhibition of cytokinesis by a lipid metabolite, psychosine. J. Cell Biol. 149 (2000) 943-950
92. Im D.S., Heise C.E., Nguyen T., O'Dowd B.F., and Lynch K.R. Identification of a molecular target of psychosine and its role in globoid cell formation. J. Cell Biol. 153 (2001) 429-434
93. Radu C.G., Cheng D., Nijagal A., Riedinger M., McLaughlin J., Yang L.V., Johnson J., and Witte O.N. Normal immune development and glucocorticoid-induced thymocyte apoptosis in mice deficient for the T-cell death-associated gene 8 receptor. Mol. Cell. Biol. 26 (2006) 668-677
94. Belaud-Rotureau M.A., Lacombe F., Durrieu F., Vial J.P., Lacoste L., Bernard P., and Belloc F. Ceramide-induced apoptosis occurs independently of caspases and is decreased by leupeptin. Cell Death Differ. 6 (1999) 788-795
95. Engedal N., and Saatcioglu F. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 46 (2001) 289-297
96. Ramos B., Lahti J.M., Claro E., and Jackowski S. Prevalence of necrosis in C2-ceramide-induced cytotoxicity in NB16 neuroblastoma cells. Mol. Pharmacol. 64 (2003) 502-511
97. Susin S.A., Zamzami N., Castedo M., Daugas E., Wang H.G., Geley S., Fassy F., Reed J.C., and Kroemer G. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J. Exp. Med. 186 (1997) 25-37
98. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., Bodmer J.L., Schneider P., Seed B., and Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1 (2000) 489-495
99. Mimeault M. New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer. FEBS Lett. 530 (2002) 9-16
100. Lopez-Marure R., Gutierrez G., Mendoza C., Ventura J.L., Sanchez L., Reyes Maldonado E., Zentella A., and Montano L.F. Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. Biochem. Biophys. Res. Commun. 293 (2002) 1028-1036
101. van Helvoort A., van't Hof W., Ritsema T., Sandra A., and van Meer G. Conversion of diacylglycerol to phosphatidylcholine on the basolateral surface of epithelial (Madin-Darby canine kidney) cells. Evidence for the reverse action of a sphingomyelin synthase. J. Biol. Chem. 269 (1994) 1763-1769
102. Sawai H., Domae N., and Okazaki T. Current status and perspectives in ceramide-targeting molecular medicine. Curr. Pharm. Des. 11 (2005) 2479-2487
103. Yamaoka S., Miyaji M., Kitano T., Umehara H., and Okazaki T. Expression cloning of a human cDNA restoring sphingomyelin synthesis and cell growth in sphingomyelin synthase-defective lymphoid cells. J. Biol. Chem. 279 (2004) 18688-18693
104. Huitema K., van den Dikkenberg J., Brouwers J.F., and Holthuis J.C. Identification of a family of animal sphingomyelin synthases. EMBO J. 23 (2004) 33-44
105. Luberto C., and Hannun Y.A. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C?. J. Biol. Chem. 273 (1998) 14550-14559
106. Bourteele S., Hausser A., Doppler H., Horn-Muller J., Ropke C., Schwarzmann G., Pfizenmaier K., and Muller G. Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic Kym-1 cells. J. Biol. Chem. 273 (1998) 31245-31251
107. Watanabe M., Kitano T., Kondo T., Yabu T., Taguchi Y., Tashima M., Umehara H., Domae N., Uchiyama T., and Okazaki T. Increase of nuclear ceramide through caspase-3-dependent regulation of the "sphingomyelin cycle" in Fas-induced apoptosis. Cancer Res. 64 (2004) 1000-1007
108. Miyaji M., Jin Z.X., Yamaoka S., Amakawa R., Fukuhara S., Sato S.B., Kobayashi T., Domae N., Mimori T., Bloom E.T., Okazaki T., and Umehara H. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J. Exp. Med. 202 (2005) 249-259
109. Santana P., Pena L.A., Haimovitz-Friedman A., Martin S., Green D., McLoughlin M., Cordon-Cardo C., Schuchman E.H., Fuks Z., and Kolesnick R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86 (1996) 189-199
110. De Maria R., Rippo M.R., Schuchman E.H., and Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J. Exp. Med. 187 (1998) 897-902
111. Cremesti A., Paris F., Grassme H., Holler N., Tschopp J., Fuks Z., Gulbins E., and Kolesnick R. Ceramide enables fas to cap and kill. J. Biol. Chem. 276 (2001) 23954-23961
112. Grassme H., Schwarz H., and Gulbins E. Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 284 (2001) 1016-1030
113. Grassme H., Jekle A., Riehle A., Schwarz H., Berger J., Sandhoff K., Kolesnick R., and Gulbins E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276 (2001) 20589-20596
114. Grassme H., Jendrossek V., Bock J., Riehle A., and Gulbins E. Ceramide-rich membrane rafts mediate CD40 clustering. J. Immunol. 168 (2002) 298-307
115. Bezombes C., Grazide S., Garret C., Fabre C., Quillet-Mary A., Muller S., Jaffrezou J.P., and Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104 (2004) 1166-1173
116. Bollinger C.R., Teichgraber V., and Gulbins E. Ceramide-enriched membrane domains. Biochim. Biophys. Acta 1746 (2005) 284-294
117. Cock J.G., Tepper A.D., de Vries E., van Blitterswijk W.J., and Borst J. CD95 (Fas/APO-1) induces ceramide formation and apoptosis in the absence of a functional acid sphingomyelinase. J. Biol. Chem. 273 (1998) 7560-7565
118. Segui B., Andrieu-Abadie N., Adam-Klages S., Meilhac O., Kreder D., Garcia V., Bruno A.P., Jaffrezou J.P., Salvayre R., Kronke M., and Levade T. CD40 signals apoptosis through FAN-regulated activation of the sphingomyelin-ceramide pathway. J. Biol. Chem. 274 (1999) 37251-37258
119. Bezombes C., Segui B., Cuvillier O., Bruno A.P., Uro-Coste E., Gouaze V., Andrieu-Abadie N., Carpentier S., Laurent G., Salvayre R., Jaffrezou J.P., and Levade T. Lysosomal sphingomyelinase is not solicited for apoptosis signaling. FASEB J. 15 (2001) 297-299
120. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., Heinrich M., Merkel O., Ehrenschwender M., Adam D., Mentlein R., Kabelitz D., and Schutze S. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21 (2004) 415-428
121. Tomiuk S., Hofmann K., Nix M., Zumbansen M., and Stoffel W. Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling?. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3638-3643
122. Tomiuk S., Zumbansen M., and Stoffel W. Characterization and subcellular localization of murine and human magnesium-dependent neutral sphingomyelinase. J. Biol. Chem. 275 (2000) 5710-5717
123. Tonnetti L., Veri M.C., Bonvini E., and D'Adamio L. A role for neutral sphingomyelinase-mediated ceramide production in T cell receptor-induced apoptosis and mitogen-activated protein kinase-mediated signal transduction. J. Exp. Med. 189 (1999) 1581-1589
124. Tepper A.D., Ruurs P., Borst J., and van Blitterswijk W.J. Effect of overexpression of a neutral sphingomyelinase on CD95-induced ceramide production and apoptosis. Biochem. Biophys. Res. Commun. 280 (2001) 634-639
125. Hofmann K., Tomiuk S., Wolff G., and Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5895-5900
126. Marchesini N., Luberto C., and Hannun Y.A. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J. Biol. Chem. 278 (2003) 13775-13783
127. Aubin I., Adams C.P., Opsahl S., Septier D., Bishop C.E., Auge N., Salvayre R., Negre-Salvayre A., Goldberg M., Guenet J.L., and Poirier C. A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat. Genet. 37 (2005) 803-805
128. Marchesini N., Osta W., Bielawski J., Luberto C., Obeid L.M., and Hannun Y.A. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J. Biol. Chem. 279 (2004) 25101-25111
129. Levade T., and Jaffrezou J.P. Signalling sphingomyelinase: which, where, how and why?. Biochim. Biophys. Acta 1438 (1999) 1-17
130. Levade T., Malagarie-Cazenave S., Gouazé V., Ségui B., Tardy C., Betito S., Andrieu-Abadie N., and Cuvillier O. Ceramide in apoptosis: a revisited role. Neurochem. Res. 27 (2002) 601-607
131. Segui B., Cuvillier O., Adam-Klages S., Garcia V., Malagarie-Cazenave S., Leveque S., Caspar-Bauguil S., Coudert J., Salvayre R., Kronke M., and Levade T. Involvement of FAN in TNF-induced apoptosis. J. Clin. Invest. 108 (2001) 143-151
132. O'Brien N.W., Gellings N.M., Guo M., Barlow S.B., Glembotski C.C., and Sabbadini R.A. Factor associated with neutral sphingomyelinase activation and its role in cardiac cell death. Circ. Res. 92 (2003) 589-591
133. Krut O., Wiegmann K., Kashkar H., Yazdanpanah B., and Kronke M. Novel TNF-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J. Biol. Chem. 281 (2006) 13784-13793
134. Maceyka M., Sankala H., Hait N.C., Le Stunff H., Liu H., Toman R., Collier C., Zhang M., Satin L.S., Merrill Jr. A.H., Milstien S., and Spiegel S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem. 280 (2005) 37118-37129
135. Le Stunff H., Galve-Roperh I., Peterson C., Milstien S., and Spiegel S. Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. J. Cell Biol. 158 (2002) 1039-1049
136. Reiss U., Oskouian B., Zhou J., Gupta V., Sooriyakumaran P., Kelly S., Wang E., Merrill Jr. A.H., and Saba J.D. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J. Biol. Chem. 279 (2004) 1281-1290
137. Spiegel S., and Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J. Biol. Chem. 277 (2002) 25851-25854
138. Spiegel S., and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev., Mol. Cell Biol. 4 (2003) 397-407
139. Pchejetski D., Golzio M., Bonhoure E., Calvet C., Doumerc N., Garcia V., Mazerolles C., Rischmann P., Teissie J., Malavaud B., and Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 65 (2005) 11667-11675
140. Strelow A., Bernardo K., Adam-Klages S., Linke T., Sandhoff K., Kronke M., and Adam D. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J. Exp. Med. 192 (2000) 601-612
141. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40 (1997) S3-S8 (Suppl.)
142. Lavie Y., Fiucci G., Czarny M., and Liscovitch M. Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells. Lipids 34 (1999) S57-S63 (Suppl.)
143. Bleicher R.J., and Cabot M.C. Glucosylceramide synthase and apoptosis. Biochim. Biophys. Acta 1585 (2002) 172-178
144. Veldman R.J., Klappe K., Hinrichs J., Hummel I., van der Schaaf G., Sietsma H., and Kok J.W. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J. 16 (2002) 1111-1113
145. Hummel I., Klappe K., and Kok J.W. Up-regulation of lactosylceramide synthase in MDR1 overexpressing human liver tumour cells. FEBS Lett. 579 (2005) 3381-3384
146. Tepper A.D., Diks S.H., van Blitterswijk W.J., and Borst J. Glucosylceramide synthase does not attenuate the ceramide pool accumulating during apoptosis induced by CD95 or anti-cancer regimens. J. Biol. Chem. 275 (2000) 34810-34817
147. Veldman R.J., Mita A., Cuvillier O., Garcia V., Klappe K., Medin J.A., Campbell J.D., Carpentier S., Kok J.W., and Levade T. The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J. 17 (2003) 1144-1146
148. Norris-Cervetto E., Callaghan R., Platt F.M., Dwek R.A., and Butters T.D. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J. Biol. Chem. 279 (2004) 40412-40418
149. Jaffrezou J.P., Levade T., Bettaieb A., Andrieu N., Bezombes C., Maestre N., Vermeersch S., Rousse A., and Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15 (1996) 2417-2424
150. Bezombes C., Plo I., Mansat-De Mas V., Quillet-Mary A., Negre-Salvayre A., Laurent G., and Jaffrezou J.P. Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C. FASEB J. 15 (2001) 1583-1585
151. Senchenkov A., Litvak D.A., and Cabot M.C. Targeting ceramide metabolism-A strategy for overcoming drug resistance. J. Natl. Cancer Inst. 93 (2001) 347-357
152. Morales A., Colell A., Mari M., Garcia-Ruiz C., and Fernandez-Checa J.C. Glycosphingolipids and mitochondria: role in apoptosis and disease. Glycoconjugate J. 20 (2004) 579-588
153. Abe A., Radin N.S., Shayman J.A., Wotring L.L., Zipkin R.E., Sivakumar R., Ruggieri J.M., Carson K.G., and Ganem B. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res. 36 (1995) 611-621
154. di Bartolomeo S., and Spinedi A. Differential chemosensitizing effect of two glucosylceramide synthase inhibitors in hepatoma cells. Biochem. Biophys. Res. Commun. 288 (2001) 269-274
155. Kok J.W., Veldman R.J., Klappe K., Koning H., Filipeanu C.M., and Muller M. Differential expression of sphingolipids in MRP1 overexpressing HT29 cells. Int. J. Cancer 87 (2000) 172-178
156. Crawford K.W., Bittman R., Chun J., Byun H.S., and Bowen W.D. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell. Mol. Biol. (Noisy-le-Grand) 49 (2003) 1017-1023
157. Struckhoff A.P., Bittman R., Burow M.E., Clejan S., Elliott S., Hammond T., Tang Y., and Beckman B.S. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J. Pharmacol. Exp. Ther. 309 (2004) 523-532
158. Samsel L., Zaidel G., Drumgoole H.M., Jelovac D., Drachenberg C., Rhee J.G., Brodie A.M., Bielawska A., and Smyth M.J. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58 (2004) 382-393
159. Selzner M., Bielawska A., Morse M.A., Rudiger H.A., Sindram D., Hannun Y.A., and Clavien P.A. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 61 (2001) 1233-1240
160. Stover T.C., Sharma A., Robertson G.P., and Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res. 11 (2005) 3465-3474
161. Johnson C.R., Chun J., Bittman R., and Jarvis W.D. Intrinsic cytotoxicity and chemomodulatory actions of novel phenethylisothiocyanate sphingoid base derivatives in HL-60 human promyelocytic leukemia cells. J. Pharmacol. Exp. Ther. 309 (2004) 452-461
162. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., and Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004) 355-360
163. Shinomiya T., Li X.K., Amemiya H., and Suzuki S. An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60. Immunology 91 (1997) 594-600
164. Matsuda T., Nakajima H., Fujiwara I., Mizuta N., and Oka T. Caspase requirement for the apoptotic death of WR19L-induced by FTY720. Transplant. Proc. 30 (1998) 2355-2357
165. Nagahara Y., Ikekita M., and Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J. Immunol. 165 (2000) 3250-3259
166. Matsuoka Y., Nagahara Y., Ikekita M., and Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 138 (2003) 1303-1312
167. Sonoda Y., Yamamoto D., Sakurai S., Hasegawa M., Aizu-Yokota E., Momoi T., and Kasahara T. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun. 281 (2001) 282-288
168. Azuma H., Takahara S., Ichimaru N., Wang J.D., Itoh Y., Otsuki Y., Morimoto J., Fukui R., Hoshiga M., Ishihara T., Nonomura N., Suzuki S., Okuyama A., and Katsuoka Y. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 62 (2002) 1410-1419
169. Wang J.D., Takahara S., Nonomura N., Ichimaru N., Toki K., Azuma H., Matsumiya K., Okuyama A., and Suzuki S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 40 (1999) 50-55
170. Permpongkosol S., Wang J.D., Takahara S., Matsumiya K., Nonomura N., Nishimura K., Tsujimura A., Kongkanand A., and Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int. J. Cancer 98 (2002) 167-172
171. Chua C.W., Lee D.T., Ling M.T., Zhou C., Man K., Ho J., Chan F.L., Wang X., and Wong Y.C. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer 117 (2005) 1039-1048
172. Azuma H., Takahara S., Horie S., Muto S., Otsuki Y., and Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol. 169 (2003) 2372-2377
173. Lee T.K., Man K., Ho J.W., Sun C.K., Ng K.T., Wang X.H., Wong Y.C., Ng I.O., Xu R., and Fan S.T. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 25 (2004) 2397-2405
174. Ho J.W., Man K., Sun C.K., Lee T.K., Poon R.T., and Fan S.T. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther. 4 (2005) 1430-1438
175. Yasui H., Hideshima T., Raje N., Roccaro A.M., Shiraishi N., Kumar S., Hamasaki M., Ishitsuka K., Tai Y.T., Podar K., Catley L., Mitsiades C.S., Richardson P.G., Albert R., Brinkmann V., Chauhan D., and Anderson K.C. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 65 (2005) 7478-7484
176. Brinkmann V., Wilt C., Kristofic C., Nikolova Z., Hof R.P., Chen S., Albert R., and Cottens S. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant. Proc. 33 (2001) 3078-3080
177. Azuma H., Horie S., Muto S., Otsuki Y., Matsumoto K., Morimoto J., Gotoh R., Okuyama A., Suzuki S., Katsuoka Y., and Takahara S. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. AntiCancer Res. 23 (2003) 3183-3193
178. Shayman J.A., Deshmukh G.D., Mahdiyoun S., Thomas T.P., Wu D., Barcelon F.S., and Radin N.S. Modulation of renal epithelial cell growth by glucosylceramide. Association with protein kinase C, sphingosine, and diacylglycerol. J. Biol. Chem. 266 (1991) 22968-22974
179. Rani C.S., Abe A., Chang Y., Rosenzweig N., Saltiel A.R., Radin N.S., and Shayman J.A. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J. Biol. Chem. 270 (1995) 2859-2867
180. Liu Y.Y., Han T.Y., Giuliano A.E., and Cabot M.C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem. 274 (1999) 1140-1146
181. Liu Y.Y., Han T.Y., Giuliano A.E., Hansen N., and Cabot M.C. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem. 275 (2000) 7138-7143
182. Lavie Y., Cao H., Bursten S.L., Giuliano A.E., and Cabot M.C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 271 (1996) 19530-19536
183. Lavie Y., Cao H., Volner A., Lucci A., Han T.Y., Geffen V., Giuliano A.E., and Cabot M.C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem. 272 (1997) 1682-1687
184. Spinedi A., Bartolomeo S.D., and Piacentini M. Apoptosis induced by N-hexanoylsphingosine in CHP-100 cells associates with accumulation of endogenous ceramide and is potentiated by inhibition of glucocerebroside synthesis. Cell Death Differ. 5 (1998) 785-791
185. Nicholson K.M., Quinn D.M., Kellett G.L., and Warr J.R. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br. J. Cancer 81 (1999) 423-430
186. Lucci A., Han T.Y., Liu Y.Y., Giuliano A.E., and Cabot M.C. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int. J. Oncol. 15 (1999) 541-546
187. Deng W., Li R., and Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J. Natl. Cancer Inst. 92 (2000) 912-917
188. Sietsma H., Veldman R.J., Kolk D., Ausema B., Nijhof W., Kamps W., Vellenga E., and Kok J.W. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin. Cancer Res. 6 (2000) 942-948
189. Olshefski R.S., and Ladisch S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int. J. Cancer 93 (2001) 131-138
190. Cabot M.C., Giuliano A.E., Han T.Y., and Liu Y.Y. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. 59 (1999) 880-885
191. Lucci A., Han T.Y., Liu Y.Y., Giuliano A.E., and Cabot M.C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 86 (1999) 300-311
192. Inokuchi J., Jimbo M., Momosaki K., Shimeno H., Nagamatsu A., and Radin N.S. Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res. 50 (1990) 6731-6737
193. Weiss M., Hettmer S., Smith P., and Ladisch S. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res. 63 (2003) 3654-3658
194. Guerrera M., and Ladisch S. N-butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset. Cancer Lett. 201 (2003) 31-40
195. Berkers C.R., and Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol. Sci. 26 (2005) 252-257
196. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., Iizasa T., Nakayama T., Taniguchi M., and Fujisawa T. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 1910-1917
197. Liu Y.Y., Han T.Y., Giuliano A.E., and Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 15 (2001) 719-730
198. Liu Y.Y., Han T.Y., Yu J.Y., Bitterman A., Le A., Giuliano A.E., and Cabot M.C. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J. Lipid Res. 45 (2004) 933-940
199. De Maria R., Lenti L., Malisan F., d'Agostino F., Tomassini B., Zeuner A., Rippo M.R., and Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science 277 (1997) 1652-1655
200. Colell A., Morales A., Fernandez-Checa J.C., and Garcia-Ruiz C. Ceramide generated by acidic sphingomyelinase contributes to tumor necrosis factor-alpha-mediated apoptosis in human colon HT-29 cells through glycosphingolipids formation. Possible role of ganglioside GD3. FEBS Lett. 526 (2002) 135-141
201. Watanabe R., Ohyama C., Aoki H., Takahashi T., Satoh M., Saito S., Hoshi S., Ishii A., Saito M., and Arai Y. Ganglioside G(M3) overexpression induces apoptosis and reduces malignant potential in murine bladder cancer. Cancer Res. 62 (2002) 3850-3854
202. Tokuyama S., Moriya S., Taniguchi S., Yasui A., Miyazaki J., Orikasa S., and Miyagi T. Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA. Int. J. Cancer 73 (1997) 410-415
203. Ségui B., Bezombes C., Uro-Coste E., Medin J.A., Andrieu-Abadie N., Auge N., Brouchet A., Laurent G., Salvayre R., Jaffrezou J.P., and Levade T. Stress-induced apoptosis is not mediated by endolysosomal ceramide. FASEB J. 14 (2000) 36-47
204. Koybasi S., Senkal C.E., Sundararaj K., Spassieva S., Bielawski J., Osta W., Day T.A., Jiang J.C., Jazwinski S.M., Hannun Y.A., Obeid L.M., and Ogretmen B. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J. Biol. Chem. 279 (2004) 44311-44319
205. Olivera A., Kohama T., Edsall L., Nava V., Cuvillier O., Poulton S., and Spiegel S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147 (1999) 545-558
206. Edsall L.C., Cuvillier O., Twitty S., Spiegel S., and Milstien S. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J. Neurochem. 76 (2001) 1573-1584
207. Bonhoure E., Pchejetski D., Aouali N., Morjani H., Levade T., Kohama T., and Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20 (2006) 95-102
208. Bektas M., Jolly P.S., Muller C., Eberle J., Spiegel S., and Geilen C.C. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24 (2005) 178-187
209. Le Scolan E., Pchejetski D., Banno Y., Denis N., Mayeux P., Vainchenker W., Levade T., and Moreau-Gachelin F. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 106 (2005) 1808-1816
210. Liu H., Toman R.E., Goparaju S.K., Maceyka M., Nava V.E., Sankala H., Payne S.G., Bektas M., Ishii I., Chun J., Milstien S., and Spiegel S. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem. 278 (2003) 40330-40336
211. Igarashi N., Okada T., Hayashi S., Fujita T., Jahangeer S., and Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem. 278 (2003) 46832-46839
212. Mandala S.M., Thornton R., Galve-Roperh I., Poulton S., Peterson C., Olivera A., Bergstrom J., Kurtz M.B., and Spiegel S. Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1- phosphate and induces cell death. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7859-7864
213. Min J., Van Veldhoven P.P., Zhang L., Hanigan M.H., Alexander H., and Alexander S. Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner. Mol. Cancer Res. 3 (2005) 287-296
214. Raisova M., Goltz G., Bektas M., Bielawska A., Riebeling C., Hossini A.M., Eberle J., Hannun Y.A., Orfanos C.E., and Geilen C.C. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett. 516 (2002) 47-52
215. Macchia M., Barontini S., Bertini S., Di Bussolo V., Fogli S., Giovannetti E., Grossi E., Minutolo F., and Danesi R. Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. J. Med. Chem. 44 (2001) 3994-4000
216. Bieberich E., Kawaguchi T., and Yu R.K. N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells. J. Biol. Chem. 275 (2000) 177-181
217. Bieberich E., Hu B., Silva J., MacKinnon S., Yu R.K., Fillmore H., Broaddus W.C., and Ottenbrite R.M. Synthesis and characterization of novel ceramide analogs for induction of apoptosis in human cancer cells. Cancer Lett. 181 (2002) 55-64
218. Bieberich E., Silva J., Wang G., Krishnamurthy K., and Condie B.G. Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants. J. Cell Biol. 167 (2004) 723-734
219. Niiro H., Azuma H., Tanago S., Matsumura K., Shikata K., Tachibana T., and Ogino K. (3Z)-2-Acetylamino-3-octadecen-1-ol as a potent apoptotic agent against HL-60 cells. Bioorg. Med. Chem. 12 (2004) 45-51
220. Novgorodov S.A., Szulc Z.M., Luberto C., Jones J.A., Bielawski J., Bielawska A., Hannun Y.A., and Obeid L.M. Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J. Biol. Chem. 280 (2005) 16096-16105
221. Rossi M.J., Sundararaj K., Koybasi S., Phillips M.S., Szulc Z.M., Bielawska A., Day T.A., Obeid L.M., Hannun Y.A., and Ogretmen B. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol.-Head Neck Surg. 132 (2005) 55-62
222. Dagan A., Wang C., Fibach E., and Gatt S. Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death. Biochim. Biophys. Acta 1633 (2003) 161-169
223. Darroch P.I., Dagan A., Granot T., He X., Gatt S., and Schuchman E.H. A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death. J. Lipid Res. 46 (2005) 2315-2324
224. Obeid L.M., Taha T.A., and Mullen T.D. A house divided: Ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim. Biophys. Acta 1758 (2006) 2027-2036
225. Spiegel S., Hait N.C., Oskeritzian C.A., Paugh S.W., and Milsten S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 1758 (2006) 2016-2026
226. Cabot M.C., and Gouaze-Andersson V. A house divided: Ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell. Biochim. Biophys. Acta 1758 (2006) 2095-2102